INGAVIRIN

Active material: Imidazoliletanamid pentandiovoy acid (vitaglutam)
When ATH: J05AX
CCF: Viricide
ICD-10 codes (testimony): J10
When CSF: 09.01.05.02
Manufacturer: Valenti PHARMACEUTICS JSC (Russia)

Pharmaceutical form, composition and packaging

Capsules of blue color, size №2; contents of capsules – granules and powder white or white with Valium a color shade.

Excipients: lactose, potato starch, colloidal silicon dioxide (aэrosyl), magnesium stearate.

Ingredients of the capsule shell: Titanium dioxide, dye Brilliant Black (Black Diamond), patented blue dye (Patent blue), carmine dye (poncho 4R), azoruʙin, gelatin.

7 PC. – packings Valium planimetric (1) – packs.

Capsules of red color, size №1; contents of capsules – granules and powder white or white with Valium a color shade.

Excipients: lactose, potato starch, colloidal silicon dioxide (aэrosyl), magnesium stearate.

Ingredients of the capsule shell: Titanium dioxide, quinoline yellow, carmine dye (poncho 4R), azoruʙin, gelatin.

7 PC. – packings Valium planimetric (1) – packs.

Pharmacological action

Viricide. It is active against influenza A and influenza B, adenoviral infection.

In experiments in vitro and in vivo to effectively inhibit reproduction and cytopathic effect of the virus of influenza A and influenza B, Adenovirus. The antiviral mechanism of action caused by the suppression of viral reproduction at step Nuclear phase, delayed migration of newly synthesized NP virus from the cytoplasm to the nucleus.

It has a modulating effect on the functional activity of interferon: It causes an increase in the content of interferon in the blood to physiological norms, It stimulates and normalizes the reduced α-interferonprodutsiruyuschuyu ability of white blood cells, It stimulates γ-interferonprodutsiruyuschuyu ability of white blood cells.

It causes the generation of cytotoxic lymphocytes, and increases the content of NK T-lymphocytes, possessing high killer activity against virus-transformed cells and a pronounced antiviral activity.

The anti-inflammatory effect is due to inhibition of the production of key proinflammatory cytokines (FNOα, ИЛ-1b и ИЛ-6), reduction of myeloperoxidase activity.

The therapeutic efficacy of the flu is manifested in shortening the period of fever, reduction intoxication (headache, weakness, dizziness), catarrhal symptoms, reducing the number of complications and duration of the disease.

Pharmacokinetics

Absorption and distribution

When used in the recommended doses definition plasma drug available methods it is not possible.

In experimental studies using radioactive label was established, that the drug rapidly enters the blood from the gastrointestinal tract and is distributed evenly over the internal organs.

C_max in blood, blood plasma and most organs are achieved through 30 minutes after administration. AUC values ​​kidney, liver and lungs slightly higher than AUC blood (43.77 g × h / g). AUC values ​​spleen, adrenal, lymph nodes and thymus enlarge blood AUC. The average retention time of the drug in the blood – 37.2 no.

At 5-day course of oral administration 1 time / day is its accumulation in internal organs and tissues. Moreover the qualitative characteristics of pharmacokinetic curves after each injection were identical: a rapid increase of drug concentration following each administration and then slowly fall to 24 sometimes.

Metabolism and excretion

Do not metabolized in the body and is excreted unchanged in.

The basic process excretion occurs within 24 no. During this time the output 80% dose. For the first 5 h output 34.8%, in the following hours – 45.2%. Of those displayed in the feces 77%, urine – 23%.

Testimony

- Treatment of Influenza (if necessary – in conjunction with the reception of symptomatic drugs).

Dosage regimen

The drug is taken orally by 90 mg 1 times / day for 5 days, regardless of the meal.

The drug should be started with the appearance of the first symptoms of the disease, not later 36 h From the onset of illness.

Side effect

Rarely: allergic reactions.

Contraindications

- Pregnancy;

- Childhood and adolescence up 18 years;

- Hypersensitivity to the drug.

Pregnancy and lactation

Use of the drug during pregnancy has not been studied.

If necessary, use during lactation should decide the issue of termination of breastfeeding.

Cautions

Toxicological studies indicate low toxicity and high safety profile of the drug (LD₅₀ exceeds the therapeutic dose is more than 3000 time).

Established, that the preparation has no mutagenic and carcinogenic, It did not affect reproductive function, It does not have immunotoxic and allergenic properties, does not have any irritant action.

Effects on ability to drive vehicles and management mechanisms

Ingavirin^® no sedative action, It does not affect the speed of psychomotor reactions, the drug can be used in people of different professions, incl. require attention and coordination.

Overdose

Cases of overdose Ingavirin^® not disclosed.

Drug Interactions

Not recommended simultaneous application Ingavirin^® with other antiviral drugs.

Occasions interaction Ingavirin^® with other drugs is not detected.

Conditions of supply of pharmacies

The drug is released under the prescription.

Conditions and terms

The drug should be stored out of reach of children, dry, dark place at a temperature no higher than 25 ° C. Shelf life – 2 year.